Pediatrix Medical Group reported strong fourth-quarter results, driven by top-line outperformance, completion of portfolio restructuring, and overhead expense reductions. Net revenue increased to $502.4 million, with a net income of $30.5 million, or $0.36 per share. Adjusted EPS was $0.51, and Adjusted EBITDA reached $68.7 million.
Net revenue for the quarter was $502.4 million, an increase compared to the prior-year period.
Net income was $30.5 million, or $0.36 per diluted share.
Adjusted EPS was $0.51, compared to $0.32 for the fourth quarter of 2023.
Adjusted EBITDA was $68.7 million, compared to $50.8 million for the prior-year period.
Pediatrix anticipates its 2025 Adjusted EBITDA to be in the range of $215 million to $235 million.
Analyze how earnings announcements historically affect stock price performance